Novo Nordisk (NVO) Stock: Pharma Giant Inks $1.4B Partnership With Orbis for AI-Driven Oral Therapies
Novo Nordisk (NVO) announces $1.4B partnership with Orbis Medicines to develop oral therapies for cardiometabolic diseases using AI-powered technology.
The post Novo Nordisk (NVO) Stock: Pharma Giant Inks $1.4B Partnership With Orbis for AI-Driven Oral Therapies appeared first on Blockonomi.
Source: Source: Blockonomi